Skip to main content
Clinical Trials/NCT05101707
NCT05101707
Completed
Early Phase 1

Combining taVNS With Early CIMT to Improve Health Outcomes of Infants With Unilateral Upper Extremity Weakness

Medical University of South Carolina1 site in 1 country6 target enrollmentApril 1, 2022

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Infant Development
Sponsor
Medical University of South Carolina
Enrollment
6
Locations
1
Primary Endpoint
CIMT Fidelity
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

Newborns who are born premature or suffer brain injury at birth are at risk for motor problems that may cause weakness in reaching and grasping on one side of the body. In older children, therapists may use a hand mitt and restraint for the stronger arm, to encourage use of the weaker side, called constraint-induced movement therapy (CIMT). Even with the high intensity therapy of CIMT, it typically takes between 40-120 hours total treatment time for most children to improve their motor skills. A non-invasive form of nerve stimulation, transcutaneous auricular vagus nerve stimulation (taVNS), stimulates a nerve by the ear that enhances learning motor skills. The purpose of this study is to evaluate the safety and effectiveness of taVNS to improve motor skills when paired with CIMT in infants with one-sided weakness at 6-18months of age.

Detailed Description

Recent pioneering studies have used neuromodulation combined with intensive motor therapies in adults after stroke. Few studies have investigated combining neuromodulation and evidence-based pediatric intensive therapies such as CIMT, and then only in older children with CP to enhance neuroplasticity and improve functional outcomes. The investigators are the first to use non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) paired with a motor task of bottle-feeding in infants with feeding failure. taVNS paired with motor feeding activity was safe and over 50% infants attained full oral feeds who were slated to receive a gastrostomy tube (G-tube). With the unique collaboration of experts in brain stimulation, pediatric translational clinical science and pediatric occupational therapy in this pilot project, the investigators propose to expand the paradigm of pairing neuromodulation with motor training in at-risk infants by exploring the safety, feasibility, and effectiveness of delivering taVNS concurrently with CIMT. The hypothesis is that combining taVNS with intensive CIMT may boost neuroplasticity, allowing for delivery of infant therapy at a minimally effective dosage while improving infant outcomes. The investigators aim to determine the feasibility and safety of taVNS in at-risk infants 6-18mo undergoing CIMT therapy in open label pilot trial and assess both infant tolerability and the therapist's ability to deliver high-quality CIMT along with taVNS.

Registry
clinicaltrials.gov
Start Date
April 1, 2022
End Date
February 29, 2024
Last Updated
10 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Must have all of the following:
  • 6-18 month-old infants with hemiplegia/motor asymmetry
  • Must be able to participate in high intensity CIMT
  • Gross Motor Function Classification System (GMFCS) level I-IV

Exclusion Criteria

  • Must have none of the following:
  • GMFCS level V
  • severe motor impairment/quadriplegic involvement
  • uncorrected blindness or deafness
  • cardiomyopathy

Outcomes

Primary Outcomes

CIMT Fidelity

Time Frame: at 1 month

Feasibility of delivering high fidelity CIMT therapy sessions while the therapist is also triggering taVNS using the Fidelity of Implementation Measure (FIRM) with scoring range (0-4), higher scores indicate greater consistency of therapy with established CIMT procedure

Quality of Upper Extremity Skills Test (QUEST), GRASP

Time Frame: 1 month

change in test of hand function and quality of movement between the right and left sides of the body, scoring range 0-100, higher scores indicate better hand function; from baseline to end of treatment

Secondary Outcomes

  • Gross Motor Function Measure-88 (GMFM-88)(1 month)

Study Sites (1)

Loading locations...

Similar Trials